Official Report 407KB pdf
The final item of business is a members’ business debate on motion S7M-01170, in the name of Jenni Minto, on brain tumour tissue preservation and patient choice in Scotland. The debate will be concluded without any question being put. I ask members who wish to speak in the debate to press their request-to-speak button.
Motion debated,
That the Parliament notes concerns raised by the Campaign for Owain’s Law regarding what it sees as substantial variation in the fresh-freezing of brain tumour tissue following surgery across NHS Scotland; notes research by the campaign indicating that around a quarter (23%) of specimens reported across Scotland’s four main neuro-oncology NHS boards in 2025 were fresh-frozen, with significant variation between centres; understands that, once sufficient tissue for diagnosis has been secured, fresh-freezing suitable remaining tumour tissue can preserve future opportunities for advanced testing, personalised treatments, clinical trials and research; notes the view that diagnosis must always come first and that not every specimen will be suitable for freezing; considers that substantial variation in practice risks creating a postcode lottery in whether potentially valuable tissue is preserved; notes the belief that patients should receive clear and consistent information and meaningful choice regarding the storage and future use of their tissue, and further notes the calls for a consistent national approach to brain tumour tissue preservation across Scotland, including in the Argyll and Bute constituency, under which suitable remaining tissue is routinely fresh-frozen where clinically feasible, patient choice is protected and preserved tissue can better support future treatment, testing and research.
17:16
I am grateful for the opportunity to bring this important debate to the Parliament and I thank colleagues across the chamber who have supported my motion.
I begin with a simple point: when someone undergoes surgery for brain cancer, what happens to their tumour tissue could determine which treatment options remain available to them in the future—yet, across Scotland, those opportunities are not consistently being protected.
That was my motivation for securing this debate in support of Ellie James and the campaign for Owain’s law. Ellie lost her husband, Owain, to brain cancer and has since worked tirelessly to ensure that other families do not unknowingly lose potentially vital treatment opportunities in the same way as he did. I am pleased that Owain’s cousin, Gareth, is here with us today—it is particularly meaningful to have a member of Owain’s family present while we discuss the campaign that was launched in his memory.
I am so honoured to have met Ellie. What a force she is. I am always blown away by families and friends who, when impacted by a loss, focus on what they can do to ensure that the things that led to their circumstances are not repeated for others.
In September, I hosted Ellie in the Scottish Parliament. She brought a life-sized replica medical freezer for MSPs to sign in support of the campaign. I was struck by the interest that colleagues showed and the strength of their feelings about improving opportunities for people living with brain cancer.
My central request to the Scottish Government is straightforward: a formal national policy that makes routine fresh-freezing and long-term preservation of suitable brain tumour tissue the standard across the national health service in Scotland, backed by a published implementation plan and timetable.
Ellie’s campaign began with the most devastating personal experience. Her husband, Owain, was diagnosed with a stage 4 brain tumour in August 2022. He was 34 years old, with a young daughter, Amelia. Owain and Ellie were determined to fight for their future. During surgery, half of Owain’s tumour was removed, but only around 1cm—of an available 7cm—was fresh-frozen, leaving very little material suitable for the personalised cancer vaccine treatment that he later pursued. That tissue produced just three vaccine doses; Ellie believes that preserving more could have allowed for closer to 30 doses.
Following his vaccine treatment, scans showed complete regression of Owain’s remaining tumour. For a time, he was able to enjoy a near-normal quality of life with Ellie and their young daughter. It gave the family precious time together. Tragically, when his cancer returned, no further vaccine doses could be produced because no more suitably preserved tissue was available. Ellie strongly believes that, had more vaccines been available, Owain would still be alive today.
Owain died in June 2024, aged just 35. Whatever the medical uncertainties, a possible treatment opportunity was lost because of a decision about tissue preservation that neither Owain nor Ellie had been meaningfully involved in.
I also pay tribute to Kim Borthwick from Glasgow, who died in September aged just 36 after being diagnosed with glioblastoma. Kim spoke movingly about wanting more time with her husband, Ross, and their young twin boys. She wrote to the cabinet secretary to raise concerns about the lack of routine tissue freezing in Scotland. Last night, I spoke with Kim’s mum, Gillian. She told me that Kim was an amazing daughter, an amazing wife and an amazing mother, who was determined to do what she could for others. Kim said,
“It is too late for me, but I want to make a difference for those who come after me.”
I also want to welcome Tammie, who is here in the public gallery today. Her husband, Graeme, died just 11 months after being diagnosed with glioblastoma. Tammie has shared how they struggled to access the genomic testing needed to pursue potential clinical trials, and waited months simply for confirmation of whether his tumour tissue had been frozen. Those were months that Graeme simply did not have.
Who in this place has not been inspired by Scottish swimmer Archie Goodburn’s direct plea for more investment in brain cancer research? Today, I am requesting Scottish Government leadership to make that difference to protect patients’ interests. Wherever someone lives, we should be doing everything clinically appropriate to keep their future options open. As the MSP for Argyll and Bute, I am particularly conscious of the importance of equitable access to specialist healthcare.
I welcome the Scottish Government’s recognition of the issue. In October, the Cabinet Secretary for Health and Care confirmed that work is under way to improve tissue pathways for genomic testing, but she acknowledged that further work is needed on long-term storage.
When a brain tumour is removed during surgery, tissue must be preserved for diagnosis. However, the way in which any suitable remaining tissue is handled can determine whether it can be used later for advanced testing, clinical trials or personalised treatments. Fresh-freezing preserves biological material that certain emerging treatments and research techniques depend on. Once that opportunity is lost, it might be impossible to recover. This is particularly important as Scotland seeks to expand genomic medicine, including whole-genome sequencing. Appropriate tissue preservation can help to unlock the full potential of those advances.
I return to my two requests of the minister. First, will the Scottish Government commit to a formal national policy that makes routine freezing and long-term preservation of suitable brain tumour tissue the expected standard across NHS Scotland? Secondly, will it commit to publishing a national implementation plan and timetable? Alongside those two commitments, I hope that the minister will agree to meet Ellie James and involve her in taking forward that work, ensuring that patients’ experiences and interests are at the heart of the process.
We might not yet be able to offer every brain cancer patient the treatments that they desperately need, but we can do more to ensure that the treatments and opportunities of tomorrow are not lost through decisions that are made today. I hope that the Scottish Government will help to turn that ambition into a clear national commitment.
Next week, a round table is being held in Westminster, and on 16 December, there will be a debate on tissue freezing in the Senedd. I hope that the voices of my colleagues here tonight and the Scottish Government will carry loud and clear to the other United Kingdom legislators and to our health boards, and that Owain’s law will be implemented.
Ellie cannot change what happened to Owain, but, through her determination, she is trying to change what happens to the next patient and the next family. When we preserve tissue, we preserve possibilities, and when we preserve possibilities, we preserve hope.
The time limit for speeches in a members’ business debate is four minutes. I call Heather Anderson.
17:24
I thank Jenni Minto for securing the debate and for all her work to raise awareness of the issue in the Parliament. Like many, I was fortunate to be able to meet Owain’s partner, Ellie James, at Jenni’s drop-in event in September, and I was very moved by the details of the story, as I am sure members will be today. Owain’s story is powerful, and I am glad that time has been secured in the Parliament to raise the issue in the chamber.
What was particularly clear from my conversation with Ellie is the need to do what we can to ensure that there is greater access for people like Owain to newer and more personalised treatment options. Patients should not be denied access to those options just because the problem of tissue freezing has not yet been solved.
Treatments that were thought impossible a generation ago are now increasingly commonplace. Breakthroughs are happening every day around the world, and world-leading research is being carried out at the University of Dundee, where researchers are working hard on undertaking clinical trials and increasing our understanding of a range of brain disorders.
It can be no surprise, therefore, that the campaign for Owain’s law has found strong support in Dundee for improving tissue preservation. Sadly, at the moment, the pathway for that can be complicated. Although brain tumour surgery takes place in Dundee, specialist neuropathology support is largely provided in Edinburgh. In the past, that has meant that tumour specimens have initially been handled by the local pathology laboratory in Dundee and then been transported to Edinburgh. They have arrived already fixed and have therefore been no longer suitable or sufficiently fresh for freezing.
However, Tayside neurosurgeons have reportedly been really positive about the need to freeze more tissue, and I have been informed that both the local pathology laboratory and management are supportive. Although there are still some practical questions to be answered on local storage and transport, this is a completely solvable problem. The university’s research team has the ability to collect and freeze fresh tumour tissue for approved research when the process is actively co-ordinated, which demonstrates that improving tissue freezing is technically achievable. The greater issue now is to ensure that that becomes routine, as Jenni Minto said, rather than being one-off individual instances.
That brings me to reiterating why tissue freezing is so important. Earlier this week, I met a young campaigner from another organisation, and we discussed genomics testing and Scotland’s ambition to improve genomic medicine. As she had not been able to benefit from genomic testing, she had cancer treatment, resulting in adverse consequences in operations that could have been avoided. Whole genome sequencing is not yet routinely available through the NHS in Scotland, which has meant that fresh tissue freezing has become a less prominent feature of the national pathway. We can do something about that.
Better preservation can and will help to ensure that people can be better supported in the future, as technologies develop such as genomic sequencing and molecular testing. We owe it to Owain and those who might be affected in the future to make the difference now. I support the call for a national policy, which I hope will be followed by a national implementation plan.
17:27
I thank Jenni Minto for securing this important debate, and I recognise Ellie James and the Campaign for Owain’s Law for their determination to bring the issue before the Parliament. I was pleased to attend the campaign’s event in the Parliament in September and to hear more about the importance of preserving tumour tissue and the changes that are urgently needed. I also valued a meeting that I had with Ellie over the summer recess.
I know how important advances in cancer research and treatment are to patients and their families. Scotland has a proud history of medical research. There is enormous potential in personalised medicine and genomic testing to transform how we diagnose and treat cancers. However, we are not doing enough, and there is a fundamental problem: those scientific advances cannot fulfil their potential if the NHS is not equipped to support them. We can invest in groundbreaking research and develop new treatments, but, if suitable tumour tissue is not preserved following surgery, patients might never have the opportunity to benefit from that research and innovation.
Tissue freezing might sound like a minor technical detail, but it can make a fundamental difference to a patient’s future treatment options. When a tumour is removed during surgery, freezing suitable tissue preserves the possibility of it being used for advanced testing, clinical trials and emerging personalised treatments. If that opportunity is missed, it might be impossible to recover later. For some patients, it could literally be the difference between having future treatment options and having those doors closed firmly before they even start.
It was disappointing to learn from the campaign that, in 2025, only 23 per cent of brain tumour specimens reported across Scotland’s four main neuro-oncology health boards were fresh-frozen. NHS Lothian had a figure of 60 per cent, which is great; the figure for NHS Greater Glasgow and Clyde was 20 per cent; it was just 2 per cent in NHS Grampian; and it was nothing at all in NHS Tayside. That variation between health boards is simply unacceptable. Diagnosis must always come first, and not every specimen can be frozen, but surely we cannot accept a situation where a patient’s future treatment opportunities may depend on which hospital they attend or where they live.
The British Neuro-Oncology Society has already set out clear recommendations on the preservation of suitable brain tumour tissue. However, clinical guidance is effective only if hospitals have the resources and systems to put it into practice. Guidance alone will not deliver the consistency that we need.
Crucially, tissue preservation requires co-ordination between surgeons, theatre teams, pathologists and lab staff. It requires appropriate freezer capacity, reliable transport arrangements and facilities for secure long-term storage. Those arrangements must work across the entire patient pathway, including outside normal working hours. That is why this debate matters. It is not simply about how tissue is handled in a lab; it is about whether our NHS has the infrastructure, the workforce and the nationally consistent processes that are needed in order to give patients that best possible opportunity. None of that happens automatically. We cannot simply expect overstretched NHS staff to deliver those additional services without support. It is the responsibility of the Scottish Government to provide the national leadership, planning and investment needed to make it work.
I welcome the work that is already taking place in some Scottish centres. I pay tribute to the clinicians and researchers who are leading those efforts. However, it cannot be right that the preservation of suitable tumour tissue depends on the resources or arrangements that are available, depending on where the patient lives. Patients in my local area should have the same opportunities as patients in Edinburgh, Aberdeen or Dundee.
The Scottish Government has already acknowledged that further work is needed to improve tissue pathways and to assess the capacity that is required for long-term storage. That is welcome, but acknowledgement must now be followed by action. We need a national assessment of existing capacity, covering freezer provision, transport arrangements, specialist staffing and long-term storage facilities.
I want to put a straightforward question to the Scottish Government and the minister. Will the minister commit to introducing a national tissue preservation policy, supported by a published implementation plan that identifies the infrastructure, workforce and funding that are required to deliver it consistently across NHS Scotland?
The Scottish Government has an opportunity to show leadership, to remove that unnecessary variation and to ensure that every brain cancer patient in Scotland has the same opportunity to benefit from future advances. I hope that the minister will take that opportunity tonight.
17:33
I welcome the debate, and I thank Jenni Minto for bringing this important issue before the Parliament. I pay tribute to Ellie James, whose tireless campaigning has exposed deeply concerning questions about how brain tumour patients are being treated across Scotland.
I have been particularly struck by Owain’s experience and the consequences that the decisions about how his brain tumour tissue was preserved had for his treatment options. I commend Ellie for her determination to ensure that other families do not face the same, and for pushing for practical changes that could make a real difference to patient treatment options.
I will focus on a particular concern: the lack of national accountability and transparency over tissue preservation in Scotland. Whatever improvements we make to clinical guidance, we need to know that those improvements are reaching patients. At present, however, it is difficult to establish what is happening in practice. In trying to find out how widely brain tumour tissue is being preserved in Scotland, Ellie and the Campaign for Owain’s Law had to submit freedom of information requests to individual health boards, piecing together information that should have been available nationally.
The findings were deeply concerning. The campaign’s figures suggested that only 23 per cent of reported brain tumour specimens were frozen in Scotland in 2025, compared with approximately 38 per cent across the United Kingdom. Within Scotland, the variation is even more striking, with NHS Lothian reporting that around 60 per cent of specimens were frozen, while NHS Tayside recorded no specimens at all being frozen. I understand that the campaign has since spoken with clinicians in those boards who report that there has been progress in the past year.
I recognise that not every specimen can or should be frozen and that clinical considerations must come first, but differences of that magnitude raise serious questions about whether patients are receiving comparable care across all health boards. To be frank, why has it fallen to a bereaved family’s campaign to establish the scale of those differences? Surely the Scottish Government should already have that information and be using it to identify where improvements are needed.
I welcome the Government’s acknowledgement in October that further work is required on long-term tissue storage, alongside its effort to improve pathways for genomic testing. However, recognising that there is a problem is only the beginning; ministers must now demonstrate that they have been taking responsibility for addressing it. Stronger clinical guidance would certainly be welcome, but guidance on paper means very little if we cannot establish whether it is being implemented consistently or whether health boards have the facilities and resources to follow it.
Scotland needs a Government-led national audit of tissue freezing, with regular public reporting on performance across health boards. Crucially, that audit must go beyond counting how many samples are frozen. It should establish whether eligible tissue is being preserved appropriately; whether its quality is being maintained; and whether patients can actually access the tissue should they need it for future testing or treatment. Where shortcomings are identified, there must be clear responsibility for addressing them. Without that accountability, we risk introducing new standards without ever knowing whether they have changed what is actually happening in our hospitals.
I ask the minister directly if the Scottish Government will commit to a national policy and implementation plan for brain tumour tissue preservation, with clear lines of accountability and regular public reporting so that the Parliament can properly scrutinise whether patients are benefiting. Ellie and her campaign have already done an extraordinary amount to expose all these shortcomings. It should not fall to her, or to other patients and other families, to keep investigating whether the NHS is delivering improvements. That responsibility must ultimately rest with the Scottish Government, and I hope that the minister will recognise that today.
17:37
I thank Jenni Minto for securing this important members’ business debate, and for her campaigning and for hosting the drop-in event in September. It was a pleasure to meet with Ellie and to hear about Owain’s pathway and story. It demonstrated to us all that, while what is emerging around genomics is exciting, our NHS is not in the place where we can meet the challenge, and we should all want to ensure that it is moving towards that.
I take this opportunity to pay tribute to Archie Goodburn and his family. I have known Archie for many years, and their campaigning and his work have put the issue, and brain cancer, firmly on the national agenda both here and across the UK. That can only be a good thing.
As I have said, I think that there is a wider issue. I have raised it recently with the First Minister in relation to genomic testing and access to drugs that are now coming forward. The NHS will need to look towards that in the future, and I am not sure where it can sit with the NHS simplification and reform agenda. It might sit outside the NHS as well, given the investment that will be needed.
The statistics are stark, and I do not want to simply repeat them, but I reiterate that brain cancer patients across Scotland are missing out on future treatment options, clinical trials and advanced testing, simply because brain tumour tissue that is removed during surgery is not consistently frozen and stored. We have heard the statistics that show that some health boards are in a much stronger place. That includes my own health board, NHS Lothian, and it is welcome to see that level being achieved. There is a lot to learn from health boards across Scotland.
The evidence demonstrates that, although genomic testing is now fundamental to brain tumour care, the opportunity for research to also take place needs to be specifically looked at.
I pay tribute to what is now a broad coalition of charities working in this space. I welcome the reports and briefings that we received ahead of today’s debate from Brain Tumour Research, Brainstrust, the Brain Tumour Charity, OurBrainBank and the Tessa Jowell Brain Cancer Mission. It is really positive to see those charities working together and setting the agenda.
One of the questions that have already been highlighted is about the work that is going on in relation to the workforce. We need to think about what we are asking for in that regard. The level of potential tissue samples that will have to be stored in a sustainable way means that there will be a separate workforce for that in the future. A few years ago, I was lucky enough to visit the brain bank in Glasgow, and I was blown away by the generosity of the people who had donated their brains for research. However, we are now talking about people who are alive and wanting treatment. I do not think that, unless we visit these facilities, we can understand that the NHS is advancing at such a rate that we are not talking about people donating tissue but about people needing their tissue to be part of their treatment journey. We need our NHS to be up and running in relation to that in the future.
I also want to highlight something that I always mention in relevant debates and which was raised in one of the briefings that we received, which is the fact that 73 per cent of brain cancer patients are diagnosed in an emergency setting. We should not forget that, often, many young people are diagnosed at a stage that is too late for some of the treatments to be effective. We need to think about what we can do about that.
I have raised the need for us to consider the issue of earlier interventions and warning systems in a GP setting. I wonder where some of the work around that sits in this period following the election. I hope that, in closing, the minister can touch on that.
I endorse what has already been said by members. It is important that we focus on an outcome. I fully endorse the call from Jenni Minto for a firm Scottish Government commitment to make routine preservation of suitable tumour tissue a national standard. We all support that and are interested to see and hear what the minister and the Government will do to progress that.
17:42
I thank Jenni Minto for bringing this important motion to Parliament this evening, providing us with the opportunity to recognise the impact that brain cancer has on patients and their families and the urgent need to improve survival rates through improved treatment options and research.
Around 1,000 people in Scotland every year are diagnosed with brain cancer. Many are diagnosed at a later stage compared to other cancers, and that, along with other factors, limits the treatment options that are available. A diagnosis of cancer is always difficult for patients and their families, but I absolutely recognise that it can be particularly acute for those with brain cancer.
I thank the colleagues who have contributed to the debate tonight for their valuable and thoughtful contributions. There seems to be quite wide agreement on what needs to change and the actions that we should move towards taking.
I also express my sympathy for Owain James’s family, and I am pleased to acknowledge the motion’s recognition of the work of the Campaign for Owain’s Law. I thank the campaign team for its work to flag the areas that need to be addressed and the opportunities that we have to best prepare Scotland to support advanced testing, personalised treatment and clinical trials for people with brain cancer.
I am very glad that Gareth is in the gallery today. I am sorry to have missed Ellie James when she came to visit Parliament, but I would be more than happy to meet the family to discuss their issues further.
I also appreciate the work that the campaign team undertook in visiting and engaging with neuro-oncology centres and tissue biorepositories across Scotland. As we have heard today, they also collected information on the proportion of patients with brain cancer for whom fresh-frozen tumour samples were stored. They highlighted not only that those proportions are low but that there is significant variation across Scotland. I accept Jackie Baillie’s point about the variation that exists, and I agree that consistency is important. It should not matter where someone is; that treatment should be available to them.
As Miles Briggs noted in his thoughtful contribution, there is certainly space in the discussions that we are having about NHS reform to consider how we can do this better and whether there are better ways of working together to ensure consistency across Scotland.
The Scottish Government accepts the findings of the campaign. The scientists working to develop long-read whole genome sequencing for use in brain cancer, which requires fresh-frozen tissue samples, found the same pattern when they looked at it. As we implement the “Genomics in Scotland: Building our Future” strategy and offer more comprehensive testing to patients in Scotland, we must develop the robust national pathways for tissue storage and transit that are needed to support those initiatives.
One of the most important aspects of the motion is
“the need for patients to receive clear and consistent information regarding the storage and future usage of their tissue”.
Work is under way to develop a consistent consent framework to support genomic testing, and there may be scope to extend that to support tissue collection and storage. I acknowledge that that needs to be developed in close collaboration not only with patients and families but with the clinical teams who are working hard across Scotland to deliver diagnosis and care, often within very short timescales.
The Campaign for Owain’s Law points to the need for national working and collaboration to share best practice around the protocols that are used to store and collect fresh-frozen samples for future use. That is not just to support the immediate diagnosis of brain cancer and initial treatment options but to support the use of precision therapies, vaccines and access to trials in the future.
At the moment, the treatment options for many patients remain limited. We recognise that research and innovation are a core part of our NHS, and they play a key role in improving earlier diagnosis rates, enabling people with cancer to access new treatments at an earlier stage, and influencing health planning and policy. Work is ongoing to expand to Scotland the NHS cancer vaccine launch pad, with interest and engagement from across the country. We are working to ensure that all clinical trials that are offered via that platform are considered in Scotland, too.
Groundbreaking research is also taking place across Scotland’s neuro-oncology centres in collaboration with our universities. That includes early-phase clinical trials of targeted gene therapies, some of which have been developed by Scottish research centres, which offer enormous promise. For example, the ADePT trial sponsored by Trogenix, a company that is based at the BioQuarter in Edinburgh, is an early-phase clinical trial of an innovative therapy for patients with glioblastoma. The Scottish Government recognises not just the potential value of personalised cancer vaccines and gene therapies for people with brain cancer but the challenges that that raises for our healthcare system.
There are many structures in Scotland that we can draw on to help us. There is already a clinical management pathway for neuro-oncology, which is co-ordinated by the NHS Scottish cancer collaborative and published on the right decision service platform. That provides a mechanism to support delivery of consistent care across Scotland that we can build on. The chief scientist office funding for NHS Research Scotland includes support for four independently accredited biorepositories that work as a network to manage the ethical collection, storage and use of tissue from NHS patients in Scotland in research. They have a wealth of knowledge in the provision of fresh brain tissue for research, although that is generally to support specific research projects, rather than the long-term storage of samples for clinical purposes. The clinical management pathway on lung cancer already recommends the collection of biopsy material to support genomic testing, so there is much that we can learn from that. The CSO-funded NHS Research Scotland biorepository network can manage the ethical collection, storage and use of remainder tissue from NHS Scotland in specific research projects. It provides a useful foundation, but further work is needed to explore the wider storage of tissue across all tumour types.
It is vital, therefore, that we work with partners across the NHS, academia and industry to share the best practice and expertise that already exist in Scotland, and to develop tissue collection and storage protocols and processes that can support future access to personalised therapies and trials. The tissue requirements for vaccine development can vary considerably depending on the tumour type, and the platforms and companies that are involved. I acknowledge that this will be challenging, and we need to work closely with colleagues across the four nations.
I also acknowledge the importance, as set out in the motion, of prioritising diagnosis. Improving access to comprehensive genomic information within the initial weeks following a patient’s surgery has been our priority. The Scottish Government funded a national neuro-oncology genomic testing pathway as part of its 11 high-priority areas for development. I am delighted that that pathway is implemented and that clinical teams and patients are already benefiting from it. Together with industry and academic partners, we are investing in new technology to see whether there is scope to further shorten this initial diagnostic testing.
I reflect on the points made by Miles Briggs and Heather Anderson about the advances in medical science. Huge advances are being made all the time, and we need to work closely with all the people who are engaged in the research.
I thank Jenni Minto for introducing the debate and the Owain’s law campaign team for its work in raising those important issues. I pay tribute to Gillian, Tammie and Archie for all their ongoing work and, of course, to Ellie for her work on the campaign.
By continuing to invest in research, innovation and diagnostics, we can continue to improve outcomes for people who are affected by brain cancer across Scotland and to ensure that they receive the highest possible standard of care. The motion has highlighted areas where we need to work collaboratively with patients so that they can support future treatment, testing and research.
That concludes the debate.
Meeting closed at 17:50.
Previous
Decision Time